Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,503 shares of the firm's stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $12.56, for a total transaction of $31,437.68. Following the sale, the insider now directly owns 161,860 shares of the company's stock, valued at approximately $2,032,961.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Soleil Boughton also recently made the following trade(s):
- On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.95, for a total value of $34,916.85.
- On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total value of $39,171.95.
- On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total value of $965,130.57.
- On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40.
- On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17.
Hims & Hers Health Price Performance
Obama’s Forever Term [exposed]
From Porter & Company | Ad
America’s Last Election
New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power.
Power they will use to reshape America to their dark, dystopian vision.
Start streaming it now at no cost here
Shares of NYSE:HIMS opened at $12.50 on Thursday. The firm has a 50 day moving average of $13.85 and a 200 day moving average of $10.19. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $17.16.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The company had revenue of $246.60 million during the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm's quarterly revenue was up 47.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.11 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of HIMS. Oak Ridge Investments LLC purchased a new position in Hims & Hers Health during the first quarter worth approximately $2,066,000. Diversify Advisory Services LLC acquired a new stake in shares of Hims & Hers Health in the first quarter valued at about $701,000. Principal Financial Group Inc. raised its holdings in Hims & Hers Health by 17.9% in the 1st quarter. Principal Financial Group Inc. now owns 16,655 shares of the company's stock valued at $258,000 after acquiring an additional 2,525 shares during the last quarter. Cornerstone Investment Partners LLC purchased a new position in Hims & Hers Health during the first quarter worth approximately $161,000. Finally, First National Trust Co acquired a new position in shares of Hims & Hers Health during the 1st quarter valued at about $232,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms have commented on HIMS. TheStreet raised shares of Hims & Hers Health from a "d" rating to a "c" rating in a research report on Monday, March 4th. Imperial Capital upgraded Hims & Hers Health from an "in-line" rating to an "outperform" rating and set a $16.00 price target on the stock in a research note on Wednesday, February 28th. Guggenheim upped their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Tuesday, February 27th. Citigroup raised their target price on Hims & Hers Health from $12.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, February 27th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $14.85.
Check Out Our Latest Analysis on Hims & Hers Health
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
